Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Consolidation with FR or FCR in CLL
NCT00602459Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2008
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in chronic lymphocytic leukemia (CLL) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00602459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602459.